AstraZeneca Raises CEO Pay 6.4% to £17.7M ($23.9M) for 2025
AstraZeneca increased CEO Pascal Soriot's 2025 pay by 6.4% to 17.7 million pounds ($23.87 million), driven by higher annual bonuses. This remuneration keeps Soriot among the FTSE 100’s highest-paid executives.
1. Pay Rise Details
AstraZeneca raised Pascal Soriot's total 2025 remuneration by 6.4% to £17.7 million ($23.87 million), driven by an increase in his annual bonus component.
2. FTSE 100 Context
With this pay package, Soriot remains one of the highest-paid CEOs in the FTSE 100, reflecting strong company performance and achievement of bonus-linked targets.
Related News
NVDA
Nvidia Projects $20 Billion in CPU Sales Within $200 Billion Market
NVDA•
TGT
Target CEO Highlights Under-$10 Toy Sales Surge Despite High Costs
TGT•
HUBG
Hub Group Delays Q1 Earnings After Revealing 2023-24 Misstatements, Stock Falls 12.5%
HUBG•
NVDA
Nvidia’s AI Chip Revenue Forecast Beats Estimates but Shares Drop 1.3%
NVDA•
CRM
Salesforce Faces Competition from Nvidia’s $200B AI CPU, Nasdaq Rally
CRM•
Sources
FR